Litcius/Paper detail

Oxidative Stress Amplifying Polyprodrug Micelles as Drug Carriers for Combination Anticancer Therapy

Yujin Lee, Nanhee Song, Nuri Kim, Manseok Yang, Gayoung Kwon, Hyejin Hyeon, Eunkyeong Jung, Seong‐Cheol Park, Chun‐Ho Kim, Dongwon Lee

2022Biomacromolecules13 citationsDOI

Abstract

Cancer cells are more vulnerable to reactive oxygen species (ROS)-mediated oxidative stress than normal cells due to disturbed redox balance. It can be postulated that ROS-generating drug carriers exert anticancer actions, leading to combination anticancer therapy with drug payloads. Here, we report a ROS-generating polyprodrug of cinnamaldehyde (CA) that not only serves as a drug carrier but also synergizes with drug payloads. The polyprodrug of CA (pCA) incorporates ROS-generating CA in the backbone of an amphiphilic polymer through an acid-cleavable acetal linkage. pCA could self-assemble with tumor-targeting lipopeptide (DSPE-PEG-RGD) and encapsulate doxorubicin (DOX) to form T-pCAD micelles. At acidic pH, T-pCAD micelles release both CA and DOX to exert synergistic anticancer actions. Animal studies using mouse xenograft models revealed that T-pCAD micelles accumulate in tumors preferentially and suppress the tumor growth significantly. Based on the oxidative stress amplification and acid-responsiveness, ROS-generating pCAD micelles hold tremendous potential as drug carriers for combination anticancer therapy.

Topics & Concepts

MicelleChemistryOxidative stressReactive oxygen speciesDoxorubicinDrugDrug carrierOxidative phosphorylationDrug deliveryBiochemistryPharmacologyBiophysicsCancer researchBiologyChemotherapyOrganic chemistryGeneticsAqueous solutionNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsRNA Interference and Gene Delivery
Oxidative Stress Amplifying Polyprodrug Micelles as Drug Carriers for Combination Anticancer Therapy | Litcius